Mevalonate kinase deficiency and Dutch type periodic fever

被引:0
|
作者
Frenkel, J
Houten, SM
Waterham, HR
Wanders, RJA
Rijkers, GT
Kimpen, JLL
Duran, R
Poll-The, BT
Kuis, W
机构
[1] Univ Utrecht, Med Ctr, Wilhelmina Childrens Hosp, Dept Gen Pediat, NL-3508 AB Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Wilhelmina Childrens Hosp, Dept Pediat Immunol, NL-3508 AB Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Wilhelmina Childrens Hosp, Dept Metab Disorders, NL-3508 AB Utrecht, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem & Pediat, NL-1105 AZ Amsterdam, Netherlands
关键词
fever; IgD; hypergammaglobulinemia; mevalonate kinase; mevalonic acid; familial Mediterranean fever; periodicity;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Dutch type periodic fever (DPF) is an autosomal recessive hereditary fever syndrome. Cases have been reported worldwide, the majority from France and The Netherlands. From infancy the patients suffer fever attacks that recur every 2-8 weeks, often precipitated by immunizations, infections or emotional stress. Fever lasts 2-7 days and can be accompanied by malaise, headache diarrhea, abdominal pain vomiting, skin rashes, arthralgia, arthritis, tender lymphadenopathy: hepatosplenomegaly and oral and genital ulcers. Labarotory evaluation during fever shows granulocytosis and elevated acute phase reactants. DPF is caused by a deficiency of the enzyme mevalonate kinase (MK). Besides DPE, the spectrum of MK deficiency includes a severe phenotype, mevalonic aciduria (MA). MA patients have less residual MK activity leading to substantially higher urinary, mevalonic acid excretion than in DPF. Mevalonic aciduria is characterized by mental retardation and dysmorphic features in addition to the clinical features of DPE At the genomic level, several mutations of varying severity have been identified The DPF phenotype is caused by one particular mild missense mutation. Most patients are compound heterozygotes for this mutation and a more severe mutation. The mechanism by which MK deficiency lends to fever is not understood. The vast majority of DPF patients have persistently, elevated serum IgD and can be classified as having hyperimmunoglobulinemia D and periodic fever syndrome (HIDS). Conversely, most HIDS patients have MK deficiency and hence DPF, but the two disorders do not overlap entirely.
引用
收藏
页码:525 / 532
页数:8
相关论文
共 50 条
  • [21] Evolutionary hypothesis of the Mevalonate Kinase Deficiency
    Vuch, J.
    Marcuzzi, A.
    Bianco, A. M.
    Tommasini, A.
    Zanin, V.
    Crovella, S.
    MEDICAL HYPOTHESES, 2013, 80 (01) : 67 - 69
  • [22] Tocilizumab for the Treatment of Mevalonate Kinase Deficiency
    Rafiq, Nadia K.
    Lachmann, Helen
    Joensen, Frodi
    Herlin, Troels
    Brogan, Paul A.
    CASE REPORTS IN PEDIATRICS, 2018, 2018
  • [23] Perinatal Onset Mevalonate Kinase Deficiency
    Steiner, Laurie A.
    Ehrenkranz, Richard A.
    Peterec, Steven M.
    Steiner, Robert D.
    Reyes-Mugica, Miguel
    Gallagher, Patrick G.
    PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2011, 14 (04) : 301 - 306
  • [24] Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome
    Joost P.H. Drenth
    Laurence Cuisset
    Gilles Grateau
    Christian Vasseur
    Saskia D. van de Velde-Visser
    Jan G.N. de Jong
    Jacques S. Beckmann
    Jos W.M. van der Meer
    Marc Delpech & contributing members of the International Hyper-IgD Study Group
    Nature Genetics, 1999, 22 : 178 - 181
  • [25] Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome
    Drenth, JPH
    Cuisset, L
    Grateau, G
    Vasseur, C
    van de Velde-Visser, SD
    de Jong, JGN
    Beckmann, JS
    van der Meer, JWM
    Delpech, M
    NATURE GENETICS, 1999, 22 (02) : 178 - 181
  • [26] An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome
    Federici, Silvia
    Vanoni, Federica
    Ben-Chetrit, Eldad
    Cantarini, Luca
    Frenkel, Joost
    Goldbach-Mansky, Raphaela
    Gul, Ahmet
    Hoffman, Hal
    Kone-Paut, Isabelle
    Kuemmerle-Deschner, Jasmin
    Lachmann, Helen J.
    Martini, Alberto
    Obici, Laura
    Ozen, Seza
    Simon, Anna
    Hofer, Michael
    Ruperto, Nicolino
    Gattorno, Marco
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (04) : 429 - 436
  • [27] Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
    Marcuzzi, Annalisa
    Crovella, Sergio
    Monasta, Lorenzo
    Brumatti, Liza Vecchi
    Gattorno, Marco
    Frenkel, Joost
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (35) : 5746 - 5752
  • [28] Mevalonate kinase somatic mosaicism and bigenic genotypes may explain heterogeneity in mevalonate kinase deficiency
    Y Shinar
    PJ Hashkes
    R Cohen
    A Kessel
    I Tirosh
    S Padeh
    J Arostegui
    A Livneh
    Pediatric Rheumatology, 13 (Suppl 1)
  • [29] Mevalonate Kinase Deficiency: About 2 Cases
    Ailal, F.
    Benhsaien, I.
    Jeddane, L.
    Najib, J.
    Bousfiha, A. A.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S193 - S193
  • [30] The enlarging clinical spectrum of mevalonate kinase deficiency
    Bader-Meunier, Brigitte
    Florkin, Benoit
    Sibilia, J.
    Aquaviva, C.
    Hachulla, E.
    Grateau, G.
    Richer, O.
    Farber, M.
    Fischbach, M.
    Hentgen, V.
    Jego, Y.
    Laroche, C.
    Neven, B.
    Lequerre, T.
    Mathian, A.
    Pellier, I.
    Touitou, I.
    Rabier, D.
    Prieur, A. M.
    Cuisset, L.
    Quartier, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 372 - 372